Previous studies have determined AIG1 may serve as a new biomarker for the diagnosis and prognostic evaluation of HCC and is associated with the thiopurine treatment of acute lymphoblastic leukemia (Choi et al., 2019). Here, AIG1 is linked to acute lymphoblastic leukemia.